Stock AFMD AFFIMED N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company Affimed N.V.

Equities

AFMD

NL0015001ZQ0

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
4.88 USD -8.79% Intraday chart for Affimed N.V. -6.69% -21.92%
Apr. 01 Wells Fargo Cuts Affimed Price Target to $25 From $30, Maintains Overweight Rating MT
Apr. 01 HC Wainwright Adjusts Affimed's Price Target to $10 From $50, Maintains Buy Rating MT

Business Summary

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.

Number of employees: 76

Sales per Business

USD in Million2022Weight2023Weight Delta
Antibodies
100.0 %
43 100.0 % 9 100.0 % -79.42%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
99.9 %
43 99.6 % 9 99.9 % -79.35%
Germany
0.1 %
0 0.4 % 0 0.1 % -96.62%

Managers

Managers TitleAgeSince
Andreas Harstrick CEO
 Chief Executive Officer 63 20-02-29
Harry Welten DFI
 Director of Finance/CFO 59 20-08-03
Wolfgang Fischer COO
 Chief Operating Officer 60 17-09-12
Mary Beth Sandin IRO
 Public Communications Contact - -
Alexander Fudukidis IRC
 Investor Relations Contact - 20-04-30
Denise Mueller PRN
 Corporate Officer/Principal 55 15-12-31
Susanne Hering HRO
 Human Resources Officer - 14-12-31

Members of the board

Members of the board TitleAgeSince
Ulrich Grau BRD
 Director/Board Member 75 15-06-30
Thomas O. Hecht CHM
 Chairman 73 06-12-31
Harry Welten DFI
 Director of Finance/CFO 59 20-08-03
Bernhard R. M. Ehmer BRD
 Director/Board Member 69 16-01-20
Uta Kemmerich-Keil BRD
 Director/Board Member 58 21-06-14
Annalisa Jenkins BRD
 Director/Board Member 58 20-08-03
Mathieu Simon BRD
 Director/Board Member 67 18-06-18
Constanze Ulmer-Eilfort BRD
 Director/Board Member 62 23-06-20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 15,227,463 14,312,712 ( 93.99 %) 0 93.99 %

Shareholders

NameEquities%Valuation
Ridgeback Capital Investments LP
9.950 %
1,485,898 9.950 % 8 M $
Gilde Healthcare Partners BV
5.441 %
812,500 5.441 % 4 M $
683 Capital Management LLC
4.687 %
700,000 4.687 % 4 M $
NEA Management Co. LLC
2.964 %
442,649 2.964 % 2 M $
Point72 Asset Management LP
2.830 %
422,582 2.830 % 2 M $
Adolf Hoess
1.698 %
253,593 1.698 % 1 M $
Millennium Management LLC
1.371 %
204,818 1.371 % 1 M $
Eversept Partners LP
1.123 %
167,668 1.123 % 888 640 $
Morgan Stanley Capital Services LLC
0.9593 %
143,265 0.9593 % 759 305 $
Vanguard Group, Inc. (Subfiler)
0.9443 %
141,025 0.9443 % 747 433 $

Company contact information

Affimed NV

Gottlieb-Daimler-Strasse 2

68165, Mannheim

+49 621 560030

http://www.affimed.com
address Affimed N.V.(AFMD)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for Affimed N.V.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
4.567 EUR
Average target price
20.83 EUR
Spread / Average Target
+356.13%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
AFFIMED N.V. Stock Affimed N.V.
-21.92% 81.47M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.51% 105B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+3.22% 97.5B
ARGENX SE Stock argenx SE
+1.86% 22.19B
BIONTECH SE Stock BioNTech SE
-16.53% 21.33B
GENMAB A/S Stock Genmab A/S
-8.49% 18.68B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.33% 16.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-20.09% 14.52B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+5.47% 14.09B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.85% 10.99B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. AFMD Stock
  4. Company Affimed N.V.